Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jorge Garcia-Martinez has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Gonzalo Soria-Alcaide

    Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

    4 shared publications
  • Manuel Ramírez

    Department of Pediatric Hematology and Oncology, Niño Jesús University Hospital, Madrid, Madrid, Spain

    4 shared publications
  • Cristina Saiz-Ladera

    Fundación para la Investigación Biomédica Hospital Infantil Universitario Niño Jesús (FIBHNJS), Madrid, Spain

    3 shared publications
  • Alejandra Reolid

    Servicio de Dermatología. Hospital Universitario de la Princesa. Instituto de Investigación Sanitaria de La Princesa (IIS-IP). Madrid

    2 shared publications
  • Alfredo J. Lucendo

    Department of Gastroenterology, Hospital General de Tomelloso, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Tomelloso, Spain

    2 shared publications
  • Ana Gómez

    Hospital Infantil Universitario Niño Jesús (HNJS) Oncohematology Department Madrid 28009

    2 shared publications

Latest Publications

  • Open Access

    crocketa: an automated Snakemake framework for integrated single-cell transcriptome and immune-repertoire analysis

    by Gonzalo Soria-Alcaide, Gonzalo García-Aguilera, Marta Portasany-Rodríguez, Jaanam Lalchandani, África González-Murillo, Elena G. Sánchez, Cristina Saiz-Ladera, Manuel Ramírez-Orellana, Jorge Garcia-Martinez

    Schematic representation of crocketa workflow. Created in BioRender: https://BioRender.com/mvjsfdh The online version contains supplementary material available at 10.1186/s12864-026-12767-y.

  • Open Access

    PULPO: pipeline of understanding large-scale patterns of oncogenomic signatures

    by Marta Portasany-Rodríguez, Gonzalo Soria-Alcaide, Elena G Sánchez, Mariya Ivanova, Ana Gómez, Reyes Giménez, Jaanam Lalchandani, Gonzalo García-Aguilera, Silvia Alemán-Arteaga, Cristina Saiz-Ladera, et al.

    PULPO v1.0 is a novel, fully automated pipeline designed for the preprocess and extraction of mutational signatures from raw Optical Genome Mapping (OGM) data. Built using Snakemake and executed within an isolated, Conda-managed environment, PULPO transforms complex cytogenetic alterations, captured at ultra-high resolution, into Catalogue of somatic mutations in cancer mutational signatures (COSMIC). This innovative approach not only enables researchers to work directly from raw OGM inputs but also streamlines the traditionally complex process of signature extraction, making advanced oncogenomic analyses accessible to users with varying levels of bioinformatics expertise. By facilitating the integration of comprehensive structural variants (SVs) and copy number variants (CNVs) data with established signature catalogues, PULPO paves the way for improved diagnostic accuracy and personalized therapeutic strategies. The pipeline is open source and freely available under the MIT License at https://github.com/OncologyHNJ/PULPO-v.1.0 and DOI in Zenodo: https://zenodo.org/records/17749097. Supplementary data are available at Bioinformatics online.

  • Open Access

    PULPO: Pipeline of understanding large-scale patterns of oncogenomic signatures

    by Marta Portasany-Rodríguez, Gonzalo Soria-Alcaide, Elena G. Sánchez, María Ivanova, Ana Gómez, Reyes Jiménez, Jaanam Lalchandani, Gonzalo García-Aguilera, Silvia Alemán-Arteaga, Cristina Saiz-Ladera, et al.

    Short Structured Summary: PULPO v1.0 is a novel, fully automated pipeline designed for the preprocess and extraction of mutational signatures from raw Optical Genome Mapping (OGM) data. Built using Snakemake and executed within an isolated, Conda-managed environment, PULPO transforms complex cytogenetic alterations, captured at ultra-high resolution, into Catalogue of somatic mutations in Cancer (COSMIC)-based mutational signatures. This innovative approach not only enables researchers to work directly from raw OGM inputs but also streamlines the traditionally complex process of signature extraction, making advanced oncogenomic analyses accessible to users with varying levels of bioinformatics expertise. By facilitating the integration of comprehensive structural variants (SVs) and copy number variants (CNVs) data with established signature catalogs, PULPO paves the way for improved diagnostic accuracy and personalized therapeutic strategies. Availability and Implementation: The pipeline is open source and freely available under the MIT License at https://github.com/OncologyHNJ/PULPO .

  • Open Access

    CROCKETA: An automated framework for comprehensive multi-omic analysis of gene expression and clonotype immune repertoire at a single-cell level

    by Gonzalo Soria-Alcaide, Gonzalo García-Aguilera, Marta Portasany-Rodriguez, Jaanam Lalchandani, África González-Murillo, Elena G. Sánchez, Cristina Saiz-Ladera, Manuel Ramírez-Orellana, Jorge Garcia-Martinez

    CROCKETA (single- C ell R epertoire O rganization & C ombined K inetics E xploration for T ranscriptomic A nalysis) is an automated and adaptable Snakemake pipeline designed to perform fundamental initial stages of single-cell analysis for both transcriptomic and immune repertoire data, with additional steps for detailed assay characterization. CROCKETA stems from the imperative need to devise an optimal methodology for integrating and analyzing single-cell RNA sequencing (scRNA-seq) alongside single-cell T-cell Receptor (scTCR-seq) or B-Cell Receptor (scBCR-seq) data in an automated way by means of state-of-the-art tools. This pipeline encompasses basic steps from primary & secondary scRNA-seq analysis (Quality Control -QC-, sequence alignment, cell-level QC and doublets removal, data preprocessing, cell clustering, cell annotation at both single cell and cluster levels, differential expression analysis, trajectory inference and functional enrichment) along with the incorporation and analysis of immune repertoire data for both B-cells and T-cells, capable of accommodating both human and mouse datasets. The analysis can be conducted from either FastQ-formatted raw data or from expression matrices itself. CROCKETA opens up new horizons of possibilities by providing a reproducible, automated, and efficient solution for processing large volumes of data, addressing a challenge that had yet to be resolved in single-cell analyses.

  • Open Access

    Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response

    by Francisca Molina‐Jiménez, Lola Ugalde‐Triviño, Laura Arias‐González, Elisa Armenteros, Carlos Relaño‐Rupérez, Sergio Casabona, José Andrés Moreno‐Monteagudo, María Teresa Pérez‐Fernández, Verónica Martín‐Domínguez, Jennifer Fernández‐Pacheco, et al.

    Background: Recently, we have identified a dysregulated protein signature in the esophageal epithelium of eosinophilic esophagitis (EoE) patients including proteins associated with inflammation and epithelial barrier function; however, the effect of proton pump inhibitor (PPI) treatment on this signature is unknown. Herein, we used a proteomic approach to investigate: (1) whether PPI treatment alters the esophageal epithelium protein profile observed in EoE patients and (2) whether the protein signature at baseline predicts PPI response.Methods: We evaluated the protein signature of esophageal biopsies using a cohort of adult EoE (n = 25) patients and healthy controls (C) (n = 10). In EoE patients, esophageal biopsies were taken before (pre) and after (post) an 8‐week PPI treatment, determining the histologic response. Eosinophil count PostPPI was used to classify the patients: ≥15 eosinophils/hpf as non‐responders (non‐responder) and < 15 eosinophils/hpf as responders (R). Protein signature was determined and differentially accumulated proteins were characterized to identify altered biological processes and signaling pathways.Results: Comparative analysis of differentially accumulated proteins between groups revealed common signatures between three groups of patients with inflammation (responder‐PrePPI, non‐responder‐PrePPI, and non‐responder‐PostPPI) and without inflammation (controls and responder‐PostPPI). PPI therapy almost reversed the EoE specific esophageal protein signature, which is enriched in pathways associated with inflammation and epithelial barrier function, in responder‐PostPPI. Furthermore, we identified a set of candidate proteins to differentiate responder‐PrePPI and non‐responder‐PrePPI EoE patients before treatment.Conclusion: These findings provide evidence that PPI therapy reverses the alterations in esophageal inflammatory and epithelial proteins characterizing EoE, thereby providing new insights into the mechanism of PPI clinical response. Interestingly, our results also suggest that PPI response could be predicted at baseline in EoE.


  • Open Access

    Optical Genome Mapping as a New Tool to Overcome Conventional Cytogenetics Limitations in Patients with Bone Marrow Failure

    by June Iriondo, Ana Gómez, Josune Zubicaray, Jorge Garcia-Martinez, Lorea Abad, Carmen Matesanz, Reyes Giménez, Almudena Galán, Alejandro Sanz, Elena Sebastián, et al.

    Cytogenetic studies are essential in the diagnosis and follow up of patients with bone marrow failure syndromes (BMFSs), but obtaining good quality results is often challenging due to hypocellularity. Optical Genome Mapping (OGM), a novel technology capable of detecting most types chromosomal structural variants (SVs) at high resolution, is being increasingly used in many settings, including hematologic malignancies. Herein, we compared conventional cytogenetic techniques to OGM in 20 patients with diverse BMFSs. Twenty metaphases for the karyotype were only obtained in three subjects (15%), and no SVs were found in any of the samples. One patient with culture failure showed a gain in chromosome 1q by fluorescence in situ hybridization, which was confirmed by OGM. In contrast, OGM provided good quality results in all subjects, and SVs were detected in 14 of them (70%), mostly corresponding to cryptic submicroscopic alterations not observed by standard techniques. Therefore, OGM emerges as a powerful tool that provides complete and evaluable results in hypocellular BMFSs, reducing multiple tests into a single assay and overcoming some of the main limitations of conventional techniques. Furthermore, in addition to confirming the abnormalities detected by conventional techniques, OGM found new alterations beyond their detection limits.


  • Open Access

    Proton pump Inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction and evaluation of treatment response

    by Francisca Molina-Jiménez, Lola Ugalde-Triviño, Laura Arias-González, Carlos Relaño-Rupérez, Sergio Casabona, José Andrés Moreno-Monteagudo, María Teresa Pérez-Fernández, Verónica Martín-Domínguez, Jennifer Fernández-Pacheco, Emilio José Laserna-Mendieta, et al.

    Background: Recently, we have identified a dysregulated protein signature in the esophageal epithelium of eosinophilic esophagitis (EoE) patients; however, the effect of proton pump inhibitor (PPI) treatment on this signature is unknown. Herein, we used a proteomic approach to investigate: (1) whether PPI treatment alters the esophageal epithelium protein profile observed in EoE patients and (2) whether the protein signature at baseline predicts PPI response. Methods: We evaluated the protein signature of esophageal biopsies using a cohort of adult EoE (n=25) patients and healthy controls (C) (n=10). In EoE patients, esophageal biopsies were taken before (Pre) and after (Post) an 8-week PPI treatment, determining the histologic response. Eosinophil count PostPPI was used to classify the patients: ≥15 eosinophils/hpf as non-responders (NR) and <15 eosinophils/hpf as responders (R). Protein signature was determined and differentially accumulated proteins (DAP) were characterized to identify altered biological processes and signaling pathways. Results: High dimensional analysis of DAP between groups revealed common signatures between three groups of patients with inflammation (R-PrePPI, NR-PrePPI and NR-PostPPI) and without inflammation (C and R- PostPPI). PPI therapy almost reversed the EoE specific esophageal protein signature, which is enriched in pathways associated with inflammation and epithelial barrier function, in R-PostPPI. Furthermore, we identified a set of candidate proteins to differentiate R-PrePPI and NR-PrePPI EoE patients before treatment. Conclusion: These findings provide evidence that PPI therapy reverses the alterations in the protein profile associated with EoE. Interestingly, our results also suggest that PPI response could be predicted at baseline in EoE.


  • Open Access

    The Comet Assay in Drosophila: A Tool to Study Interactions between DNA Repair Systems in DNA Damage Responses In Vivo and Ex Vivo

    by Rubén Rodríguez, Isabel Gaivão, Leticia Aguado, Marta Espina, Jorge García, Pablo Martínez-Camblor, L. María Sierra

    The comet assay in Drosophila has been used in the last few years to study DNA damage responses (DDR) in different repair-mutant strains and to compare them to analyze DNA repair. We have used this approach to study interactions between DNA repair pathways in vivo. Additionally, we have implemented an ex vivo comet assay, in which nucleoids from treated and untreated cells were incubated ex vivo with cell-free protein extracts from individuals with distinct repair capacities. Four strains were used: wild-type OregonK (OK), nucleotide excision repair mutant mus201, dmPolQ protein mutant mus308, and the double mutant mus201;mus308. Methyl methanesulfonate (MMS) was used as a genotoxic agent. Both approaches were performed with neuroblasts from third-instar larvae; they detected the effects of the NER and dmPolQ pathways on the DDR to MMS and that they act additively in this response. Additionally, the ex vivo approach quantified that mus201, mus308, and the double mutant mus201;mus308 strains presented, respectively, 21.5%, 52.9%, and 14.8% of OK strain activity over MMS-induced damage. Considering the homology between mammals and Drosophila in repair pathways, the detected additive effect might be extrapolated even to humans, demonstrating that Drosophila might be an excellent model to study interactions between repair pathways.


  • Open Access

    CNVs Associated with Different Clinical Phenotypes of Psoriasis and Anti-TNF-Induced Palmoplantar Pustulosis

    by Alejandra Reolid, Antonio Sahuquillo-Torralba, Ancor Sanz-García, Rafael Botella-Estrada, Ester Muñoz-Aceituno, Mar Llamas-Velasco, Jorge García-Martínez, Esteban Daudén, Francisco Abad-Santos, María C. Ovejero-Benito

    Background: Psoriasis can present different phenotypes and could affect diverse body areas. In contrast to the high effectiveness of biological drugs in the treatment of trunk and extremities plaque psoriasis, in palmoplantar phenotypes and in plaque scalp psoriasis, these same drugs usually have reduced efficacy. Anti-TNF drugs could induce the appearance of palmoplantar pustulosis (PPP) in patients with other inflammatory diseases. The objective of this study is to identify if there are DNA Copy Number Variations (CNVs) associated with these different clinical phenotypes, which could justify the differences found in clinical practice. Moreover, we intend to elucidate if anti-TNF-induced PPP has a similar genetic background to idiopathic PPP. Methods: Skin samples were collected from 39 patients with different patterns of psoriasis and six patients with anti-TNF-induced PPP. The CNVs were obtained from methylation array data (Illumina Infinium Human Methylation) using the conumee R package. Results: No significant CNVs were found between the different phenotypes and the locations of psoriasis compared. Nevertheless, we found two significant bins harboring five different genes associated with anti-TNF-induced PPP in patients with a different background other than psoriasis. Conclusions: Our results may help to predict which patients could develop anti-TNF-induced PPP.


  • Open Access

    Variant pathogenic prediction by locus variability, the importance of the last picture of evolution

    by Jose Luis Cabrera-Alarcon, Jose Antonio Enriquez, Jorge Garcia Martinez, Fátima Sánchez-Cabo

    Accurate pathogenic detection for single nucleotide variants (SNVs) is a key problem to perform variant ranking in whole exome sequencing studies. Several in silico tools have been developed to identify deleterious variants. Locus variability, computed as Shannon entropy from gnomAD/helixMTdb variant allele frequencies can be used as pathogenic variants predictor. In this study we evaluate the use of Shannon entropy in non-coding mitochondrial DNA and also in coding regions with an additional selective pressure other than that imposed by the genetic code, as are splice-sites. To benchmark this functionality in non-coding mitochondrial variants, Shannon entropy was compared with HmtVar disease score, outperforming it in non-coding SNVs (AUC H =0.99 in ROC curve and PR-AUC H =1.00 in Precision-recall curve). In the same way, for splice-sites’ variants, Shannon entropy was compared against two state-of-the-art ensemble predictors ada score and rf score, matching their overall performance both in ROC curves (AUC H =0.95) and Precision-recall curves (PR-AUC=0.97). Therefore, locus variability could aid in variant ranking process for these specific types of SNVs. Contact: jlcabreraa@cnic.es ; fscabo@cnic.es